Showing 2721-2730 of 4703 results for "".
Pipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigThe Microbiome in Acne: Where are We Now?
https://practicaldermatology.com/topics/acne-rosacea/the-microbiome-in-acne-where-are-we-now/23731/As research reveals connections of the microbiome to skin disease, clinicians may discover new approaches to managing the disease.Emollient-Based Therapy for AD: A Potential Role for Rebalancing the Microbiome
https://practicaldermatology.com/issues/supplements/emollient-based-therapy-for-ad-a-potential-role-for-rebalancing-the-microbiome/23136/Re-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-re-introducing-ortho-dermatologics-tremfya-approved-obagi-acquired/18458/Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkumaDermWireTV: Pfizer, AbbVie JAKs for AD; Spray-on-Skin; Lubriderm Scholarships
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pfizer-abbvie-jaks-for-ad-spray-on-skin-lubriderm-scholarships/20043/For the treatment of refractory moderate-to-severe atopic dermatitis, FDA has approved Pfizer’s Cibinqo (abrocitinib) for adults and AbbVie’s Rinvoq (upadacitinib) for patients 12 and older. Researchers at the Houston Methodist Research Institute have paired their patented RNA technologies with AvitAllergan Commemorates 25th Anniversary of the First Two Approved Uses of BOTOX® (onabotulinumtoxinA)
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/allergan-commemorates-25th-anniversary-of-the-first-two-approved-uses-of-botox-onabotulinumtoxina-/19136/Allergan, Inc. (NYSE: AGN) today announced the launch of a video recognizing the physician pioneers and patient communities who contributed to the development of BOTOX® (onabotulinumtoxinA), one of the most recognized pharmaceutical brands in the United States. The video kicks off a year-long campaiDermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourWe Care: Ten Tips on Building Patient Rapport
https://practicaldermatology.com/topics/practice-management/we-care-ten-tips-on-building-patient-rapport/22908/Relationships should be nurtured by anyone with whom patients have contact during their visit.Affirming the Benefits of Full Body Skin Exams… And Overcoming Obstacles
https://practicaldermatology.com/topics/general-topics/PD0909_08-php/22772/Dermatologist-initiated full body skin exams identify skin cancers when they are most treatable. So why are some patients still not receiving exams?Build Backlinks to Boost Your Dermatology SEO
https://practicaldermatology.com/topics/practice-management/build-backlinks-to-boost-your-dermatology-seo/23257/Understand why backlinks matter. And how to get them.